greeksoup/ stock research

Turning Point Brands, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 9 November 2026: press release. Guidance figures: 1 narrowed, 2 kept. The quarter’s numbers.

Key takeaways

  • Net sales rose, profit fell: Total net sales rose 27.0% to $151.1 million. Net income attributable to Turning Point Brands fell 81.4% to $3.9 million, and diluted EPS was $0.19, against $1.13. Source
  • Gross profit rose on Modern Oral: Gross profit rose 20.9% to $85.2 million, which the company attributed to Modern Oral growth. Operating income was $9.9 million, against $25.9 million a year earlier. Source
  • Adjusted EBITDA fell with marketing spend: Adjusted EBITDA fell 41.3% to $18.4 million, which the company said includes increased sales and marketing investments. Adjusted diluted EPS was $0.41, against $1.05. Source
  • Modern Oral sales more than doubled: Modern Oral gross sales rose 114.2% to $93.9 million, and net sales rose 102.9% to $74.4 million. Modern Oral accounted for 49.2% of total company net sales. Source
  • SG&A rose 69.1%: SG&A expenses rose 69.1% to $75.3 million, which the company said includes Modern Oral sales and marketing investments and higher outbound freight costs. Source
  • Cash $251.3 million, net debt $48.7 million: Cash was $251.3 million and net debt $48.7 million at September 30, 2026, against net debt of $31.7 million at June 30, 2026. Total liquidity was $322.8 million. Source
  • Repurchases of $10.0 million in quarter: The company repurchased 167,161 shares at an average of $59.82 per share, a $10.0 million cost. The nine-month cash flow shows the same cost, with no repurchases in the prior-year period. Source
  • Modern Oral guidance reaffirmed: Full-year Modern Oral gross sales of $330-$350 million and net sales of $260-$270 million were reaffirmed, the same as in the second-quarter release. Source

“I have been involved with Turning Point Brands for nearly 14 years and have never been more optimistic about its future.”

David Glazek, Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Modern Oral gross sales SourceFiscal 2026 (full year)$330-$350 millionKept
Modern Oral net sales SourceFiscal 2026 (full year)$260-$270 millionKept
Adjusted EBITDA SourceFiscal 2026 (full year)$70-$80 millionNarrowed, top end cut from $70-90 million

What changed from last quarter

  • Guidance lowered: Full-year Adjusted EBITDA range is $70-$80 million, against $70-90 million in the second-quarter release. The release says full-year guidance was reaffirmed. Source
  • New: David Glazek is CEO. The second-quarter release named Graham Purdy as President and CEO. Source
  • New: Share repurchases appear in the quarter. The six months to June 30, 2026 showed no repurchases in the cash flow statement. Source
  • Ended: Free Cash Flow no longer appears among the non-GAAP measures listed in this release. Source

Results and growth drivers

  • Net sales rose, profit fell: Total net sales rose 27.0% to $151.1 million. Net income attributable to Turning Point Brands fell 81.4% to $3.9 million, and diluted EPS was $0.19, against $1.13. Source
  • Gross profit rose on Modern Oral: Gross profit rose 20.9% to $85.2 million, which the company attributed to Modern Oral growth. Operating income was $9.9 million, against $25.9 million a year earlier. Source
  • Adjusted EBITDA fell with marketing spend: Adjusted EBITDA fell 41.3% to $18.4 million, which the company said includes increased sales and marketing investments. Adjusted diluted EPS was $0.41, against $1.05. Source

Segments and Modern Oral

  • Stoker's sales rose 52.0%: Stoker's segment net sales rose 52.0% to $113.8 million, driven by triple-digit growth in Modern Oral. Segment gross profit rose 41.5% to $63.7 million. Source
  • Stoker's margin fell on product mix: Stoker's gross profit as a share of net sales fell to 56.0% from 60.2%. The company attributed this mainly to a shift in product mix toward Modern Oral. Source
  • Zig-Zag sales declined 15.5%: Zig-Zag segment net sales fell 15.5% to $37.3 million, and segment gross profit fell 15.6% to $21.4 million. Gross profit as a share of net sales was 57.4%, against 57.5%. Source
  • Modern Oral sales more than doubled: Modern Oral gross sales rose 114.2% to $93.9 million, and net sales rose 102.9% to $74.4 million. Modern Oral accounted for 49.2% of total company net sales. Source

“We delivered another quarter of strong results, highlighted by continued growth in Modern Oral and progress across our heritage brands.”

David Glazek, Chief Executive Officer

Costs and adjusted items

  • SG&A rose 69.1%: SG&A expenses rose 69.1% to $75.3 million, which the company said includes Modern Oral sales and marketing investments and higher outbound freight costs. Source
  • Tax rate for 2026 set at 20.5%: The quarterly tax adjustment uses a projected 2026 tax rate of 20.5%, against 22% shown in the second-quarter release. The 2025 rate used was 21.0%. Source
  • Manufacturing start-up costs excluded: Manufacturing start-up costs of $0.6 million are excluded from Adjusted EBITDA as non-recurring expenses from starting up manufacturing lines. Source
  • FDA PMTA costs excluded: Costs for FDA PMTA applications were $3.2 million, against $0.5 million a year earlier, and are excluded from Adjusted EBITDA. Source
  • Insurance-claim litigation costs excluded: Non-recurring legal expenses of $0.6 million relate to litigation over an insurance claim, against $0.4 million a year earlier. Source

Liquidity and capital allocation

  • Cash $251.3 million, net debt $48.7 million: Cash was $251.3 million and net debt $48.7 million at September 30, 2026, against net debt of $31.7 million at June 30, 2026. Total liquidity was $322.8 million. Source
  • Repurchases of $10.0 million in quarter: The company repurchased 167,161 shares at an average of $59.82 per share, a $10.0 million cost. The nine-month cash flow shows the same cost, with no repurchases in the prior-year period. Source
  • Operating cash flow fell, inventory rose: Nine-month operating cash flow was $9.4 million, against $32.5 million a year earlier. Inventories rose to $139.4 million from $108.0 million at December 31, 2025. Source

“Our investments in FRE and ALP are expanding distribution, strengthening consumer engagement and positioning us to become a leading player in the rapidly growing nicotine pouch category.”

David Glazek, Chief Executive Officer

Guidance for 2026

  • Modern Oral guidance reaffirmed: Full-year Modern Oral gross sales of $330-$350 million and net sales of $260-$270 million were reaffirmed, the same as in the second-quarter release. Source
  • Adjusted EBITDA top end lowered: Full-year Adjusted EBITDA is $70-$80 million, against $70-90 million in the second-quarter release. The release describes guidance as reaffirmed. Source
  • Guidance update dated September 21: The release says full-year 2026 guidance was updated on September 21, 2026, and reaffirms it in this release. Source

Strategy and leadership

  • David Glazek serves as CEO: David Glazek, Chief Executive Officer, said he has been involved with the company for nearly 14 years and is excited to serve as CEO. Source
  • CEO cites confidence in strategy: Glazek said he has tremendous confidence in the company's team, brands and strategy, and has never been more optimistic about its future. Source
  • FRE and ALP investment expanding reach: Management said investments in FRE and ALP are expanding distribution and consumer engagement, and positioning the company in nicotine pouches. Source

Figures management reported

FigureReported
Modern Oral gross sales (Q3 2026) Source$93.9 million
Modern Oral net sales (Q3 2026) Source$74.4 million
Modern Oral share of total company net sales Source49.2%
Retail outlets in North America Sourcemore than 220,000

Risks management discussed

  • Regulatory: FDA PMTA application costs rose to $3.2 million, against $0.5 million a year earlier, and are excluded from Adjusted EBITDA. Source
  • Financial: Stoker's gross margin fell as product mix shifted toward Modern Oral, which the company cited as the driver. Source
  • Operational: SG&A rose with Modern Oral sales and marketing investments and higher outbound freight costs. Source
  • Demand: Zig-Zag segment net sales fell 15.5%; the release does not give a cause for the decline. Source

Earlier plans management reported on

  • Not stated: The release says full-year 2026 guidance was updated on September 21, 2026 and is reaffirmed here. It gives no status beyond the reaffirmation. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.